Genmab is an international biotechnology company that has been transforming cancer treatment for over two decades. Founded in 1999, Genmab has established itself as a leader in antibody therapeutics, with a proven track record of creating breakthrough medicines that improve patients' lives. The company has successfully developed multiple approved antibody therapeutics that are marketed globally, bringing innovative treatments to patients with cancer and other serious diseases.
With headquarters in Denmark and offices across the Netherlands, United States, Japan, and the United Kingdom, Genmab operates as a truly global organization. The company's expertise spans the entire antibody development process, from discovery through commercialization, leveraging proprietary technology platforms to create differentiated therapeutics. Genmab's pipeline includes numerous investigational medicines in clinical development, reflecting the company's commitment to pushing the boundaries of antibody science to address unmet medical needs.